Indaptus net loss narrows 66% to $1.8 million in Q2 FY26
INDP•Q2 loss narrows as expenses fall
Indaptus posted a Q2 net loss of USD 1.8 million, narrowing from USD 5.2 million a year earlier; loss per share improved to USD 0.02.
R&D expense plunged 83% to USD 363,127, reflecting lower Decoy20 Phase 1 clinical costs plus payroll cuts after headcount reductions.
G&A expense fell 37% to USD 1.45 million on lower payroll-related costs plus changes in public-company costs during a management transition.
Capital position and strategic update
The company completed a USD 12 million private placement at USD 0.6 per share; ended Q2 with USD 7.6 million cash plus USD 4 million short-term investments.
Indaptus halted Decoy20 enrollment with no participants remaining, leaving no active clinical programs; it began a neurology and sleep research collaboration while weighing strategic alternatives.
